Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry

Elisa Gremese, Gianfranco Ferraccioli, F Atzeni, P Sarzi Puttini, C Botsios, A Carletto, P Cipriani, Eg Favalli, E Frati, V Foschi, S Gasparini, A Giardina, F Iannone, M Sebastiani, T Ziglioli, D Biasi, C Ferri, M Galeazzi, R Gerli, R GiacomelliR Gorla, M Govoni, G Lapadula, A Marchesoni, F Salaffi, L Punzi, G Triolo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

112 Citazioni (Scopus)

Abstract

To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register.
Lingua originaleEnglish
pagine (da-a)225-229
Numero di pagine5
RivistaAUTOIMMUNITY REVIEWS
Volume12
DOI
Stato di pubblicazionePubblicato - 2012

Keywords

  • anti-TNF therapy
  • rheumatoid arthritis

Fingerprint Entra nei temi di ricerca di 'Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry'. Insieme formano una fingerprint unica.

Cita questo